Cryoport, Inc. (CYRX) 10-Year Financial Performance & Capital Metrics

CYRX • • Industrial / General

IndustrialsFreight & LogisticsSpecialized & Temperature-Controlled LogisticsLife Sciences & Pharma Logistics

AboutCryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.Show more

Revenue $233M -1.7%
EBITDA -$88M -859.3%
Net Income -$100M -166.8%
EPS (Diluted) -2.21 -137.6%
Gross Margin 42.59% -2.7%
EBITDA Margin -37.59% -875.8%
Operating Margin -49.37% -267.2%
Net Margin -42.69% -171.4%
ROE -22.36% -212.8%
ROIC -11.78% -346.6%
Debt/Equity 0.62 -26.7%
Interest Coverage -20.93 -302.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 83 (top 17%)
✓Strong 5Y sales CAGR of 47.0%
✓Trading near 52-week high
✓Trading at only 1.4x book value

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y50.41%

5Y47.03%

3Y1.57%

TTM-0.35%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM142.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM134.66%

ROCE

10Y Avg-68.19%

5Y Avg-6.28%

3Y Avg-6.64%

Latest-14.85%

Peer Comparison

Life Sciences & Pharma Logistics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CJMBCALLAN JMB INC.	19.42M	4.20	-4.83	-50.29%	-112.68%	-159.6%	2.55%	0.29
CYRXCryoport, Inc.	564.28M	11.27	-5.10	-1.7%	35.52%	13.11%		0.62
HKPDHong Kong Pharma Digital Technology Holdings Limited	8.77M	0.80	-265.67	21.72%	-0.13%	-0.59%	4.72%	0.48

Profit & Loss

	Mar 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	5.88M	7.68M	11.95M	19.63M	33.94M	78.7M	222.61M	222.61M	237.28M	233.25M
Revenue Growth %	0.49%	0.31%	0.56%	0.64%	0.73%	1.32%	1.83%	0%	0.07%	-0.02%
Cost of Goods Sold+	3.99M	4.58M	5.99M	9.39M	16.59M	42.36M	126.03M	126.03M	133.4M	133.92M
COGS % of Revenue	0.68%	0.6%	0.5%	0.48%	0.49%	0.54%	0.57%	0.57%	0.56%	0.57%
Gross Profit+	1.89M	3.1M	5.97M	10.24M	17.35M	36.33M	96.58M	96.58M	103.87M	99.33M
Gross Margin %	0.32%	0.4%	0.5%	0.52%	0.51%	0.46%	0.43%	0.43%	0.44%	0.43%
Gross Profit Growth %	0.62%	0.64%	0.92%	0.72%	0.69%	1.09%	1.66%	0%	0.08%	-0.04%
Operating Expenses+	10.63M	11.87M	13.86M	18.88M	35.03M	66.34M	114.41M	114.41M	135.78M	214.49M
OpEx % of Revenue	1.81%	1.55%	1.16%	0.96%	1.03%	0.84%	0.51%	0.51%	0.57%	0.92%
Selling, General & Admin	10.08M	11.27M	12.65M	17.04M	31.29M	56.86M	97.56M	97.56M	120.06M	146.88M
SG&A % of Revenue	1.71%	1.47%	1.06%	0.87%	0.92%	0.72%	0.44%	0.44%	0.51%	0.63%
Research & Development	550.26K	598.11K	1.21M	1.84M	3.74M	9.48M	16.84M	16.84M	15.72M	18.04M
R&D % of Revenue	0.09%	0.08%	0.1%	0.09%	0.11%	0.12%	0.08%	0.08%	0.07%	0.08%
Other Operating Expenses	-9.9K	-6.77K	14.34K	77.63K	0	0	0	0	0	49.57M
Operating Income+	-8.74M	-8.77M	-7.89M	-8.64M	-17.68M	-30.01M	-17.83M	-17.83M	-31.9M	-115.16M
Operating Margin %	-1.49%	-1.14%	-0.66%	-0.44%	-0.52%	-0.38%	-0.08%	-0.08%	-0.13%	-0.49%
Operating Income Growth %	-0.56%	-0%	0.1%	-0.1%	-1.04%	-0.7%	0.41%	0%	-0.79%	-2.61%
EBITDA+	-8.5M	-8.39M	-7.23M	-7.79M	-15.26M	-20.14M	2.42M	2.42M	-9.14M	-87.67M
EBITDA Margin %	-1.45%	-1.09%	-0.6%	-0.4%	-0.45%	-0.26%	0.01%	0.01%	-0.04%	-0.38%
EBITDA Growth %	-0.58%	0.01%	0.14%	-0.08%	-0.96%	-0.32%	1.12%	0%	-4.78%	-8.59%
D&A (Non-Cash Add-back)	239.23K	374.2K	664.83K	857.94K	2.42M	9.87M	20.25M	20.25M	22.77M	27.49M
EBIT	-8.75M	-13.79M	-7.88M	-9.47M	-16.9M	-30.18M	-269.15M	-269.15M	-28.95M	-93.84M
Net Interest Income+	-1.07M	-139.42K	-15.69K	-69.25K	-1.37M	-2.56M	-4.69M	-4.69M	-6.14M	-5.5M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	1.07M	139.42K	15.69K	69.25K	1.37M	2.56M	4.69M	4.69M	6.14M	5.5M
Other Income/Expense	-1.08M	-4.34M	-1.36K	-891.03K	-595K	-2.73M	-256.01M	-256.01M	-3.19M	15.81M
Pretax Income+	-9.82M	-13.11M	-7.89M	-9.54M	-18.27M	-32.74M	-273.84M	-273.84M	-35.09M	-99.35M
Pretax Margin %	-1.67%	-1.71%	-0.66%	-0.49%	-0.54%	-0.42%	-1.23%	-1.23%	-0.15%	-0.43%
Income Tax+	3.63K	5.67K	5.14K	19.95K	62K	-45K	1.69M	1.69M	2.24M	239K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1.01%	1.01%	1.06%	1%
Net Income+	-9.82M	-13.11M	-7.9M	-9.56M	-18.33M	-32.69M	-275.53M	-275.53M	-37.33M	-99.59M
Net Margin %	-1.67%	-1.71%	-0.66%	-0.49%	-0.54%	-0.42%	-1.24%	-1.24%	-0.16%	-0.43%
Net Income Growth %	-0.4%	-0.34%	0.4%	-0.21%	-0.92%	-0.78%	-7.43%	0%	0.86%	-1.67%
Net Income (Continuing)	-9.82M	-13.11M	-7.9M	-9.56M	-18.33M	-32.69M	-275.53M	-275.53M	-37.33M	-99.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.34	-0.92	-0.34	-0.34	-0.55	-1.94	-6.18	-6.18	-0.93	-2.21
EPS Growth %	0.41%	0.31%	0.63%	0%	-0.62%	-2.53%	-2.19%	0%	0.85%	-1.38%
EPS (Basic)	-1.34	-0.92	-0.34	-0.34	-0.55	-1.94	-6.18	-6.18	-0.93	-2.21
Diluted Shares Outstanding	7.87M	14.22M	22.96M	28.21M	33.39M	38.58M	45.93M	45.93M	48.99M	48.74M
Basic Shares Outstanding	7.87M	14.2M	22.96M	28.21M	33.39M	38.58M	45.93M	45.93M	48.99M	48.74M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.21M	6.1M	17.3M	51.77M	102.97M	147.16M	693.52M	604.18M	535.11M	341.57M
Cash & Short-Term Investments	5.25M	4.52M	15.04M	47.26M	94.3M	93.32M	628.8M	523.32M	456.75M	261.75M
Cash Only	5.25M	2.79B	15.04M	37.33M	47.23M	36.87M	139.1M	36.59M	46.35M	45.29M
Short-Term Investments	0	-2.79B	0	9.93M	47.06M	56.44M	489.7M	486.73M	410.41M	216.46M
Accounts Receivable	616.78K	1.2M	1.63M	3.54M	7.1M	31.38M	39.41M	43.86M	42.07M	45.78M
Days Sales Outstanding	38.27	56.83	49.63	65.9	76.33	145.53	64.62	71.91	64.72	71.63
Inventory	52.88K	89.5K	114.8K	220.51K	474K	10.54M	16.5M	27.68M	26.21M	22.47M
Days Inventory Outstanding	4.84	7.14	7	8.58	10.43	90.77	47.79	80.16	71.7	61.24
Other Current Assets	288.96K	0	0	0	0	0	0	9.32M	10.08M	11.57M
Total Non-Current Assets+	1.25M	2.02M	2.97M	4.85M	32.91M	405.25M	419.45M	434.57M	422.63M	361.92M
Property, Plant & Equipment	875.67K	1.65M	2.51M	4.36M	16.29M	44.08M	69.7M	90.48M	117.51M	136.03M
Fixed Asset Turnover	6.72x	4.66x	4.76x	4.50x	2.08x	1.79x	3.19x	2.46x	2.02x	1.71x
Goodwill	0	0	0	0	11M	145.28M	146.95M	151.12M	108.4M	51.66M
Intangible Assets	13.48K	5K	90.65K	137.22K	5.18M	213.91M	201.43M	191.01M	194.38M	170.46M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	363.4K	363.4K	363.4K	350.84K	437K	1.98M	950K	1.02M	1.68M	2.9M
Total Assets+	7.46M	8.11M	20.26M	56.62M	135.87M	552.4M	1.11B	1.04B	957.74M	703.49M
Asset Turnover	0.79x	0.95x	0.59x	0.35x	0.25x	0.14x	0.20x	0.21x	0.25x	0.33x
Asset Growth %	1.86%	0.09%	1.5%	1.79%	1.4%	3.07%	1.01%	-0.07%	-0.08%	-0.27%
Total Current Liabilities+	2.47M	2.23M	2.19M	3.06M	5.46M	35.02M	42.65M	40.85M	45.61M	64.56M
Accounts Payable	758.7K	1.16M	1.2M	1.64M	2.5M	24.84M	28.58M	27.05M	26.05M	26.17M
Days Payables Outstanding	69.37	92.52	73.35	63.91	54.96	214.06	82.78	78.33	71.29	71.32
Short-Term Debt	981.99K	651.93K	0	0	0	0	0	60K	149K	14.44M
Deferred Revenue (Current)	0	0	0	66.31K	368K	445K	547K	439K	1000K	1000K
Other Current Liabilities	350.55K	0	56.27K	0	518K	1.39M	1.91M	3.45M	3.8M	3.71M
Current Ratio	2.51x	2.73x	7.92x	16.91x	18.85x	4.20x	16.26x	14.79x	11.73x	5.29x
Quick Ratio	2.49x	2.69x	7.86x	16.84x	18.77x	3.90x	15.88x	14.11x	11.16x	4.94x
Cash Conversion Cycle	-26.26	-28.56	-16.72	10.57	31.8	22.24	29.63	73.74	65.14	61.56
Total Non-Current Liabilities+	0	200.26K	192.2K	15.01M	4.13M	134.69M	428.5M	442.06M	423.11M	237.03M
Long-Term Debt	0	0	0	14.71M	0	116.26M	405.26M	407.06M	379.89M	185.03M
Capital Lease Obligations	0	0	0	33.16K	4.11M	12.37M	18.2M	24.94M	30.31M	45.32M
Deferred Tax Liabilities	0	0	0	0	21K	5.88M	4.02M	4.93M	2.82M	2.53M
Other Non-Current Liabilities	0	200.26K	192.2K	267.42K	0	176K	1.03M	5.13M	10.1M	4.14M
Total Liabilities	2.47M	2.43M	2.38M	18.07M	9.59M	169.71M	471.14M	482.91M	468.72M	301.59M
Total Debt+	981.99K	651.93K	0	14.77M	4.8M	130.92M	427.06M	435.91M	416M	250.7M
Net Debt	-4.27M	-2.79B	-15.04M	-22.56M	-42.43M	94.05M	287.95M	399.31M	369.66M	205.41M
Debt / Equity	0.20x	0.11x	-	0.38x	0.04x	0.34x	0.67x	0.78x	0.85x	0.62x
Debt / EBITDA	-	-	-	-	-	-	176.61x	180.28x	-	-
Net Debt / EBITDA	-	-	-	-	-	-	119.09x	165.14x	-	-
Interest Coverage	-8.20x	-62.88x	-502.93x	-124.83x	-12.93x	-11.72x	-3.80x	-3.80x	-5.19x	-20.93x
Total Equity+	4.99M	5.68M	17.89M	38.55M	126.28M	382.7M	641.83M	555.84M	489.02M	401.9M
Equity Growth %	12.99%	0.14%	2.15%	1.16%	2.28%	2.03%	0.68%	-0.13%	-0.12%	-0.18%
Book Value per Share	0.63	0.40	0.78	1.37	3.78	9.92	13.97	12.10	9.98	8.25
Total Shareholders' Equity	4.99M	5.68M	17.89M	38.55M	126.28M	382.7M	641.83M	555.84M	489.02M	401.9M
Common Stock	7.25K	17.6K	25.7K	30.32K	37K	40K	50K	48K	49K	50K
Retained Earnings	-109.35M	-123.53M	-131.43M	-140.99M	-159.32M	-192.01M	-467.54M	-542.83M	-642.42M	-757.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	3.15K	-45K	5.38M	-1.24M	-34.55M	-26.07M	-20.93M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.31M	-5.72M	-3.58M	-3.35M	-1.32M	-14.87M	8.13M	-1.85M	-757K	-16.32M
Operating CF Margin %	-1.07%	-0.74%	-0.3%	-0.17%	-0.04%	-0.19%	0.04%	-0.01%	-0%	-0.07%
Operating CF Growth %	-0.53%	0.09%	0.37%	0.06%	0.61%	-10.23%	1.55%	-1.23%	0.59%	-20.56%
Net Income	-9.82M	-13.11M	-7.9M	-9.56M	-18.33M	-32.69M	-275.53M	-37.33M	-99.59M	-114.76M
Depreciation & Amortization	239.23K	374.2K	664.83K	857.94K	2.42M	9.87M	20.25M	22.77M	27.49M	30.76M
Stock-Based Compensation	2.88M	3.12M	3.55M	5.48M	16.52M	8.92M	15.35M	20.08M	22.81M	19.7M
Deferred Taxes	0	4.37M	197.68K	453.92K	0	858K	253.79M	0	-1.98M	0
Other Non-Cash Items	0	84.78K	6.13K	899.41K	1.04M	437K	1.24M	24.7M	49.73M	56.58M
Working Capital Changes	-918.14K	-549.4K	-100.54K	-1.49M	-2.97M	-2.25M	-6.96M	-32.07M	780K	-8.61M
Change in Receivables	-469.81K	-581.2K	-441.64K	-1.96M	-3.6M	-2.62M	-7.27M	-4.14M	3.67M	-4.15M
Change in Inventory	-70.47K	-74.89K	-25.3K	-105.72K	-253K	1.32M	-5.98M	-14.2M	1.51M	3.25M
Change in Payables	313.23M	51.32K	123.25K	405.07K	570.48K	4.25M	2.87M	-6.48M	-2.77M	-76K
Cash from Investing+	-1.12M	-1.07M	-1.8M	-12.88M	-62.93M	-382.31M	-469.25M	-59.68M	36.05M	176.81M
Capital Expenditures	-1.12M	-1.07M	-1.71M	-2.91M	-5.34M	-8.92M	-23.88M	-22.11M	-38.78M	-17.25M
CapEx % of Revenue	0.19%	0.14%	0.14%	0.15%	0.16%	0.11%	0.11%	0.1%	0.16%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-5K	-85.65K	-46.57K	-73K	-751K	-1.13M	910K	-5.14M	-4.33M
Cash from Financing+	8.81M	6.14M	15.9M	38.53M	74.15M	385.58M	564.34M	-39.17M	-23.8M	-161.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.07B	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	10.88K	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.42M	-6.79M	-5.38M	-6.31M	-6.73M	-24.54M	-16.88M	-26.05M	-45.66M	-33.58M
FCF Margin %	-1.26%	-0.88%	-0.45%	-0.32%	-0.2%	-0.31%	-0.08%	-0.12%	-0.19%	-0.14%
FCF Growth %	-0.77%	0.09%	0.21%	-0.17%	-0.07%	-2.64%	0.31%	-0.54%	-0.75%	0.26%
FCF per Share	-0.94	-0.48	-0.23	-0.22	-0.20	-0.64	-0.37	-0.57	-0.93	-0.69
FCF Conversion (FCF/Net Income)	0.64x	0.44x	0.45x	0.35x	0.07x	0.45x	-0.03x	0.01x	0.02x	0.16x
Interest Paid	57.12K	9.53K	4.74K	637	707K	1.82M	3.3M	3.63M	3.4M	2.69M
Taxes Paid	3.63K	5.67K	5.14K	19.95K	14K	60K	1.31M	1.98M	1.46M	1.42M

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Equity (ROE)	-429.4%	-245.78%	-67.03%	-33.87%	-22.24%	-12.85%	-53.79%	-46.01%	-7.15%	-22.36%
Return on Invested Capital (ROIC)	-2967.11%	-	-208.09%	-68.86%	-26.56%	-8.03%	-1.9%	-1.42%	-2.64%	-11.78%
Gross Margin	32.14%	40.39%	49.91%	52.18%	51.12%	46.17%	43.38%	43.38%	43.78%	42.59%
Net Margin	-166.95%	-170.77%	-66.08%	-48.69%	-54.01%	-41.54%	-123.77%	-123.77%	-15.73%	-42.69%
Debt / Equity	0.20x	0.11x	-	0.38x	0.04x	0.34x	0.67x	0.78x	0.85x	0.62x
Interest Coverage	-8.20x	-62.88x	-502.93x	-124.83x	-12.93x	-11.72x	-3.80x	-3.80x	-5.19x	-20.93x
FCF Conversion	0.64x	0.44x	0.45x	0.35x	0.07x	0.45x	-0.03x	0.01x	0.02x	0.16x
Revenue Growth	49.47%	30.54%	55.68%	64.18%	72.94%	131.85%	182.87%	0%	6.59%	-1.7%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023
Service	-	-	55.3M	119.06M	133.88M	-	153.66M
Service Growth	-	-	-	115.31%	12.44%	-	-
Product	-	-	23.4M	103.54M	103.4M	-	74.72M
Product Growth	-	-	-	342.55%	-0.14%	-	-
Biopharmaceutical	16.48M	-	-	-	-	192.58M	-
Biopharmaceutical Growth	-	-	-	-	-	-	-
Animal Health	976K	-	-	-	-	30.38M	-
Animal Health Growth	-	-	-	-	-	-	-
Reproductive Medicine	2.17M	-	-	-	-	10.29M	-
Reproductive Medicine Growth	-	-	-	-	-	-	-
Global Biostorage	-	3.03M	-	-	-	-	-
Global Biostorage Growth	-	-	-	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023
Americas	17.88M	28.8M	49.55M	120.27M	128.21M	127.21M	126.37M
Americas Growth	-	61.11%	72.06%	142.70%	6.60%	-0.78%	-0.66%
EMEA	1.36M	-	-	-	-	-	59.6M
EMEA Growth	-	-	-	-	-	-	-
Asia Pacific	384K	618K	8.82M	-	-	-	42.42M
Asia Pacific Growth	-	60.94%	1327.99%	-	-	-	-
Europe, the Middle East and Africa (EMEA)	-	-	-	59.33M	42.16M	60.88M	-
Europe, the Middle East and Africa (EMEA) Growth	-	-	-	-	-28.95%	44.43%	-
Asia Pacific (APAC)	-	-	-	43M	66.91M	45.16M	-
Asia Pacific (APAC) Growth	-	-	-	-	55.60%	-32.51%	-
E M E A	-	4.52M	20.32M	-	-	-	-
E M E A Growth	-	-	349.17%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cryoport, Inc. (CYRX) reported $190.3M in revenue for fiscal year 2023. This represents a 34142% increase from $0.6M in 2010.

Cryoport, Inc. (CYRX) saw revenue decline by 1.7% over the past year.

Yes, Cryoport, Inc. (CYRX) is profitable, generating $67.6M in net income for fiscal year 2023 (-42.7% net margin).

Dividend & Returns

Cryoport, Inc. (CYRX) has a return on equity (ROE) of -22.4%. Negative ROE indicates the company is unprofitable.

Cryoport, Inc. (CYRX) had negative free cash flow of $32.5M in fiscal year 2023, likely due to heavy capital investments.

US Stock Screener

...

Cryoport, Inc. (CYRX) 10-Year Financial Performance & Capital Metrics

CYRX • • Industrial / General

IndustrialsFreight & LogisticsSpecialized & Temperature-Controlled LogisticsLife Sciences & Pharma Logistics

Revenue $233M -1.7%
EBITDA -$88M -859.3%
Net Income -$100M -166.8%
EPS (Diluted) -2.21 -137.6%
Gross Margin 42.59% -2.7%
EBITDA Margin -37.59% -875.8%
Operating Margin -49.37% -267.2%
Net Margin -42.69% -171.4%
ROE -22.36% -212.8%
ROIC -11.78% -346.6%
Debt/Equity 0.62 -26.7%
Interest Coverage -20.93 -302.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 83 (top 17%)
✓Strong 5Y sales CAGR of 47.0%
✓Trading near 52-week high
✓Trading at only 1.4x book value

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y50.41%

5Y47.03%

3Y1.57%

TTM-0.35%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM142.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM134.66%

ROCE

10Y Avg-68.19%

5Y Avg-6.28%

3Y Avg-6.64%

Latest-14.85%

Peer Comparison

Life Sciences & Pharma Logistics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CJMBCALLAN JMB INC.	19.42M	4.20	-4.83	-50.29%	-112.68%	-159.6%	2.55%	0.29
CYRXCryoport, Inc.	564.28M	11.27	-5.10	-1.7%	35.52%	13.11%		0.62
HKPDHong Kong Pharma Digital Technology Holdings Limited	8.77M	0.80	-265.67	21.72%	-0.13%	-0.59%	4.72%	0.48

Profit & Loss

	Mar 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	5.88M	7.68M	11.95M	19.63M	33.94M	78.7M	222.61M	222.61M	237.28M	233.25M
Revenue Growth %	0.49%	0.31%	0.56%	0.64%	0.73%	1.32%	1.83%	0%	0.07%	-0.02%
Cost of Goods Sold+	3.99M	4.58M	5.99M	9.39M	16.59M	42.36M	126.03M	126.03M	133.4M	133.92M
COGS % of Revenue	0.68%	0.6%	0.5%	0.48%	0.49%	0.54%	0.57%	0.57%	0.56%	0.57%
Gross Profit+	1.89M	3.1M	5.97M	10.24M	17.35M	36.33M	96.58M	96.58M	103.87M	99.33M
Gross Margin %	0.32%	0.4%	0.5%	0.52%	0.51%	0.46%	0.43%	0.43%	0.44%	0.43%
Gross Profit Growth %	0.62%	0.64%	0.92%	0.72%	0.69%	1.09%	1.66%	0%	0.08%	-0.04%
Operating Expenses+	10.63M	11.87M	13.86M	18.88M	35.03M	66.34M	114.41M	114.41M	135.78M	214.49M
OpEx % of Revenue	1.81%	1.55%	1.16%	0.96%	1.03%	0.84%	0.51%	0.51%	0.57%	0.92%
Selling, General & Admin	10.08M	11.27M	12.65M	17.04M	31.29M	56.86M	97.56M	97.56M	120.06M	146.88M
SG&A % of Revenue	1.71%	1.47%	1.06%	0.87%	0.92%	0.72%	0.44%	0.44%	0.51%	0.63%
Research & Development	550.26K	598.11K	1.21M	1.84M	3.74M	9.48M	16.84M	16.84M	15.72M	18.04M
R&D % of Revenue	0.09%	0.08%	0.1%	0.09%	0.11%	0.12%	0.08%	0.08%	0.07%	0.08%
Other Operating Expenses	-9.9K	-6.77K	14.34K	77.63K	0	0	0	0	0	49.57M
Operating Income+	-8.74M	-8.77M	-7.89M	-8.64M	-17.68M	-30.01M	-17.83M	-17.83M	-31.9M	-115.16M
Operating Margin %	-1.49%	-1.14%	-0.66%	-0.44%	-0.52%	-0.38%	-0.08%	-0.08%	-0.13%	-0.49%
Operating Income Growth %	-0.56%	-0%	0.1%	-0.1%	-1.04%	-0.7%	0.41%	0%	-0.79%	-2.61%
EBITDA+	-8.5M	-8.39M	-7.23M	-7.79M	-15.26M	-20.14M	2.42M	2.42M	-9.14M	-87.67M
EBITDA Margin %	-1.45%	-1.09%	-0.6%	-0.4%	-0.45%	-0.26%	0.01%	0.01%	-0.04%	-0.38%
EBITDA Growth %	-0.58%	0.01%	0.14%	-0.08%	-0.96%	-0.32%	1.12%	0%	-4.78%	-8.59%
D&A (Non-Cash Add-back)	239.23K	374.2K	664.83K	857.94K	2.42M	9.87M	20.25M	20.25M	22.77M	27.49M
EBIT	-8.75M	-13.79M	-7.88M	-9.47M	-16.9M	-30.18M	-269.15M	-269.15M	-28.95M	-93.84M
Net Interest Income+	-1.07M	-139.42K	-15.69K	-69.25K	-1.37M	-2.56M	-4.69M	-4.69M	-6.14M	-5.5M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	1.07M	139.42K	15.69K	69.25K	1.37M	2.56M	4.69M	4.69M	6.14M	5.5M
Other Income/Expense	-1.08M	-4.34M	-1.36K	-891.03K	-595K	-2.73M	-256.01M	-256.01M	-3.19M	15.81M
Pretax Income+	-9.82M	-13.11M	-7.89M	-9.54M	-18.27M	-32.74M	-273.84M	-273.84M	-35.09M	-99.35M
Pretax Margin %	-1.67%	-1.71%	-0.66%	-0.49%	-0.54%	-0.42%	-1.23%	-1.23%	-0.15%	-0.43%
Income Tax+	3.63K	5.67K	5.14K	19.95K	62K	-45K	1.69M	1.69M	2.24M	239K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1.01%	1.01%	1.06%	1%
Net Income+	-9.82M	-13.11M	-7.9M	-9.56M	-18.33M	-32.69M	-275.53M	-275.53M	-37.33M	-99.59M
Net Margin %	-1.67%	-1.71%	-0.66%	-0.49%	-0.54%	-0.42%	-1.24%	-1.24%	-0.16%	-0.43%
Net Income Growth %	-0.4%	-0.34%	0.4%	-0.21%	-0.92%	-0.78%	-7.43%	0%	0.86%	-1.67%
Net Income (Continuing)	-9.82M	-13.11M	-7.9M	-9.56M	-18.33M	-32.69M	-275.53M	-275.53M	-37.33M	-99.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.34	-0.92	-0.34	-0.34	-0.55	-1.94	-6.18	-6.18	-0.93	-2.21
EPS Growth %	0.41%	0.31%	0.63%	0%	-0.62%	-2.53%	-2.19%	0%	0.85%	-1.38%
EPS (Basic)	-1.34	-0.92	-0.34	-0.34	-0.55	-1.94	-6.18	-6.18	-0.93	-2.21
Diluted Shares Outstanding	7.87M	14.22M	22.96M	28.21M	33.39M	38.58M	45.93M	45.93M	48.99M	48.74M
Basic Shares Outstanding	7.87M	14.2M	22.96M	28.21M	33.39M	38.58M	45.93M	45.93M	48.99M	48.74M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.21M	6.1M	17.3M	51.77M	102.97M	147.16M	693.52M	604.18M	535.11M	341.57M
Cash & Short-Term Investments	5.25M	4.52M	15.04M	47.26M	94.3M	93.32M	628.8M	523.32M	456.75M	261.75M
Cash Only	5.25M	2.79B	15.04M	37.33M	47.23M	36.87M	139.1M	36.59M	46.35M	45.29M
Short-Term Investments	0	-2.79B	0	9.93M	47.06M	56.44M	489.7M	486.73M	410.41M	216.46M
Accounts Receivable	616.78K	1.2M	1.63M	3.54M	7.1M	31.38M	39.41M	43.86M	42.07M	45.78M
Days Sales Outstanding	38.27	56.83	49.63	65.9	76.33	145.53	64.62	71.91	64.72	71.63
Inventory	52.88K	89.5K	114.8K	220.51K	474K	10.54M	16.5M	27.68M	26.21M	22.47M
Days Inventory Outstanding	4.84	7.14	7	8.58	10.43	90.77	47.79	80.16	71.7	61.24
Other Current Assets	288.96K	0	0	0	0	0	0	9.32M	10.08M	11.57M
Total Non-Current Assets+	1.25M	2.02M	2.97M	4.85M	32.91M	405.25M	419.45M	434.57M	422.63M	361.92M
Property, Plant & Equipment	875.67K	1.65M	2.51M	4.36M	16.29M	44.08M	69.7M	90.48M	117.51M	136.03M
Fixed Asset Turnover	6.72x	4.66x	4.76x	4.50x	2.08x	1.79x	3.19x	2.46x	2.02x	1.71x
Goodwill	0	0	0	0	11M	145.28M	146.95M	151.12M	108.4M	51.66M
Intangible Assets	13.48K	5K	90.65K	137.22K	5.18M	213.91M	201.43M	191.01M	194.38M	170.46M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	363.4K	363.4K	363.4K	350.84K	437K	1.98M	950K	1.02M	1.68M	2.9M
Total Assets+	7.46M	8.11M	20.26M	56.62M	135.87M	552.4M	1.11B	1.04B	957.74M	703.49M
Asset Turnover	0.79x	0.95x	0.59x	0.35x	0.25x	0.14x	0.20x	0.21x	0.25x	0.33x
Asset Growth %	1.86%	0.09%	1.5%	1.79%	1.4%	3.07%	1.01%	-0.07%	-0.08%	-0.27%
Total Current Liabilities+	2.47M	2.23M	2.19M	3.06M	5.46M	35.02M	42.65M	40.85M	45.61M	64.56M
Accounts Payable	758.7K	1.16M	1.2M	1.64M	2.5M	24.84M	28.58M	27.05M	26.05M	26.17M
Days Payables Outstanding	69.37	92.52	73.35	63.91	54.96	214.06	82.78	78.33	71.29	71.32
Short-Term Debt	981.99K	651.93K	0	0	0	0	0	60K	149K	14.44M
Deferred Revenue (Current)	0	0	0	66.31K	368K	445K	547K	439K	1000K	1000K
Other Current Liabilities	350.55K	0	56.27K	0	518K	1.39M	1.91M	3.45M	3.8M	3.71M
Current Ratio	2.51x	2.73x	7.92x	16.91x	18.85x	4.20x	16.26x	14.79x	11.73x	5.29x
Quick Ratio	2.49x	2.69x	7.86x	16.84x	18.77x	3.90x	15.88x	14.11x	11.16x	4.94x
Cash Conversion Cycle	-26.26	-28.56	-16.72	10.57	31.8	22.24	29.63	73.74	65.14	61.56
Total Non-Current Liabilities+	0	200.26K	192.2K	15.01M	4.13M	134.69M	428.5M	442.06M	423.11M	237.03M
Long-Term Debt	0	0	0	14.71M	0	116.26M	405.26M	407.06M	379.89M	185.03M
Capital Lease Obligations	0	0	0	33.16K	4.11M	12.37M	18.2M	24.94M	30.31M	45.32M
Deferred Tax Liabilities	0	0	0	0	21K	5.88M	4.02M	4.93M	2.82M	2.53M
Other Non-Current Liabilities	0	200.26K	192.2K	267.42K	0	176K	1.03M	5.13M	10.1M	4.14M
Total Liabilities	2.47M	2.43M	2.38M	18.07M	9.59M	169.71M	471.14M	482.91M	468.72M	301.59M
Total Debt+	981.99K	651.93K	0	14.77M	4.8M	130.92M	427.06M	435.91M	416M	250.7M
Net Debt	-4.27M	-2.79B	-15.04M	-22.56M	-42.43M	94.05M	287.95M	399.31M	369.66M	205.41M
Debt / Equity	0.20x	0.11x	-	0.38x	0.04x	0.34x	0.67x	0.78x	0.85x	0.62x
Debt / EBITDA	-	-	-	-	-	-	176.61x	180.28x	-	-
Net Debt / EBITDA	-	-	-	-	-	-	119.09x	165.14x	-	-
Interest Coverage	-8.20x	-62.88x	-502.93x	-124.83x	-12.93x	-11.72x	-3.80x	-3.80x	-5.19x	-20.93x
Total Equity+	4.99M	5.68M	17.89M	38.55M	126.28M	382.7M	641.83M	555.84M	489.02M	401.9M
Equity Growth %	12.99%	0.14%	2.15%	1.16%	2.28%	2.03%	0.68%	-0.13%	-0.12%	-0.18%
Book Value per Share	0.63	0.40	0.78	1.37	3.78	9.92	13.97	12.10	9.98	8.25
Total Shareholders' Equity	4.99M	5.68M	17.89M	38.55M	126.28M	382.7M	641.83M	555.84M	489.02M	401.9M
Common Stock	7.25K	17.6K	25.7K	30.32K	37K	40K	50K	48K	49K	50K
Retained Earnings	-109.35M	-123.53M	-131.43M	-140.99M	-159.32M	-192.01M	-467.54M	-542.83M	-642.42M	-757.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	3.15K	-45K	5.38M	-1.24M	-34.55M	-26.07M	-20.93M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.31M	-5.72M	-3.58M	-3.35M	-1.32M	-14.87M	8.13M	-1.85M	-757K	-16.32M
Operating CF Margin %	-1.07%	-0.74%	-0.3%	-0.17%	-0.04%	-0.19%	0.04%	-0.01%	-0%	-0.07%
Operating CF Growth %	-0.53%	0.09%	0.37%	0.06%	0.61%	-10.23%	1.55%	-1.23%	0.59%	-20.56%
Net Income	-9.82M	-13.11M	-7.9M	-9.56M	-18.33M	-32.69M	-275.53M	-37.33M	-99.59M	-114.76M
Depreciation & Amortization	239.23K	374.2K	664.83K	857.94K	2.42M	9.87M	20.25M	22.77M	27.49M	30.76M
Stock-Based Compensation	2.88M	3.12M	3.55M	5.48M	16.52M	8.92M	15.35M	20.08M	22.81M	19.7M
Deferred Taxes	0	4.37M	197.68K	453.92K	0	858K	253.79M	0	-1.98M	0
Other Non-Cash Items	0	84.78K	6.13K	899.41K	1.04M	437K	1.24M	24.7M	49.73M	56.58M
Working Capital Changes	-918.14K	-549.4K	-100.54K	-1.49M	-2.97M	-2.25M	-6.96M	-32.07M	780K	-8.61M
Change in Receivables	-469.81K	-581.2K	-441.64K	-1.96M	-3.6M	-2.62M	-7.27M	-4.14M	3.67M	-4.15M
Change in Inventory	-70.47K	-74.89K	-25.3K	-105.72K	-253K	1.32M	-5.98M	-14.2M	1.51M	3.25M
Change in Payables	313.23M	51.32K	123.25K	405.07K	570.48K	4.25M	2.87M	-6.48M	-2.77M	-76K
Cash from Investing+	-1.12M	-1.07M	-1.8M	-12.88M	-62.93M	-382.31M	-469.25M	-59.68M	36.05M	176.81M
Capital Expenditures	-1.12M	-1.07M	-1.71M	-2.91M	-5.34M	-8.92M	-23.88M	-22.11M	-38.78M	-17.25M
CapEx % of Revenue	0.19%	0.14%	0.14%	0.15%	0.16%	0.11%	0.11%	0.1%	0.16%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-5K	-85.65K	-46.57K	-73K	-751K	-1.13M	910K	-5.14M	-4.33M
Cash from Financing+	8.81M	6.14M	15.9M	38.53M	74.15M	385.58M	564.34M	-39.17M	-23.8M	-161.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.07B	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	10.88K	0	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.42M	-6.79M	-5.38M	-6.31M	-6.73M	-24.54M	-16.88M	-26.05M	-45.66M	-33.58M
FCF Margin %	-1.26%	-0.88%	-0.45%	-0.32%	-0.2%	-0.31%	-0.08%	-0.12%	-0.19%	-0.14%
FCF Growth %	-0.77%	0.09%	0.21%	-0.17%	-0.07%	-2.64%	0.31%	-0.54%	-0.75%	0.26%
FCF per Share	-0.94	-0.48	-0.23	-0.22	-0.20	-0.64	-0.37	-0.57	-0.93	-0.69
FCF Conversion (FCF/Net Income)	0.64x	0.44x	0.45x	0.35x	0.07x	0.45x	-0.03x	0.01x	0.02x	0.16x
Interest Paid	57.12K	9.53K	4.74K	637	707K	1.82M	3.3M	3.63M	3.4M	2.69M
Taxes Paid	3.63K	5.67K	5.14K	19.95K	14K	60K	1.31M	1.98M	1.46M	1.42M

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Equity (ROE)	-429.4%	-245.78%	-67.03%	-33.87%	-22.24%	-12.85%	-53.79%	-46.01%	-7.15%	-22.36%
Return on Invested Capital (ROIC)	-2967.11%	-	-208.09%	-68.86%	-26.56%	-8.03%	-1.9%	-1.42%	-2.64%	-11.78%
Gross Margin	32.14%	40.39%	49.91%	52.18%	51.12%	46.17%	43.38%	43.38%	43.78%	42.59%
Net Margin	-166.95%	-170.77%	-66.08%	-48.69%	-54.01%	-41.54%	-123.77%	-123.77%	-15.73%	-42.69%
Debt / Equity	0.20x	0.11x	-	0.38x	0.04x	0.34x	0.67x	0.78x	0.85x	0.62x
Interest Coverage	-8.20x	-62.88x	-502.93x	-124.83x	-12.93x	-11.72x	-3.80x	-3.80x	-5.19x	-20.93x
FCF Conversion	0.64x	0.44x	0.45x	0.35x	0.07x	0.45x	-0.03x	0.01x	0.02x	0.16x
Revenue Growth	49.47%	30.54%	55.68%	64.18%	72.94%	131.85%	182.87%	0%	6.59%	-1.7%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023
Service	-	-	55.3M	119.06M	133.88M	-	153.66M
Service Growth	-	-	-	115.31%	12.44%	-	-
Product	-	-	23.4M	103.54M	103.4M	-	74.72M
Product Growth	-	-	-	342.55%	-0.14%	-	-
Biopharmaceutical	16.48M	-	-	-	-	192.58M	-
Biopharmaceutical Growth	-	-	-	-	-	-	-
Animal Health	976K	-	-	-	-	30.38M	-
Animal Health Growth	-	-	-	-	-	-	-
Reproductive Medicine	2.17M	-	-	-	-	10.29M	-
Reproductive Medicine Growth	-	-	-	-	-	-	-
Global Biostorage	-	3.03M	-	-	-	-	-
Global Biostorage Growth	-	-	-	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023
Americas	17.88M	28.8M	49.55M	120.27M	128.21M	127.21M	126.37M
Americas Growth	-	61.11%	72.06%	142.70%	6.60%	-0.78%	-0.66%
EMEA	1.36M	-	-	-	-	-	59.6M
EMEA Growth	-	-	-	-	-	-	-
Asia Pacific	384K	618K	8.82M	-	-	-	42.42M
Asia Pacific Growth	-	60.94%	1327.99%	-	-	-	-
Europe, the Middle East and Africa (EMEA)	-	-	-	59.33M	42.16M	60.88M	-
Europe, the Middle East and Africa (EMEA) Growth	-	-	-	-	-28.95%	44.43%	-
Asia Pacific (APAC)	-	-	-	43M	66.91M	45.16M	-
Asia Pacific (APAC) Growth	-	-	-	-	55.60%	-32.51%	-
E M E A	-	4.52M	20.32M	-	-	-	-
E M E A Growth	-	-	349.17%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cryoport, Inc. (CYRX) reported $190.3M in revenue for fiscal year 2023. This represents a 34142% increase from $0.6M in 2010.

Cryoport, Inc. (CYRX) saw revenue decline by 1.7% over the past year.

Yes, Cryoport, Inc. (CYRX) is profitable, generating $67.6M in net income for fiscal year 2023 (-42.7% net margin).

Dividend & Returns

Cryoport, Inc. (CYRX) has a return on equity (ROE) of -22.4%. Negative ROE indicates the company is unprofitable.

Cryoport, Inc. (CYRX) had negative free cash flow of $32.5M in fiscal year 2023, likely due to heavy capital investments.